Core Insights - Milestone Scientific Inc. reported continued progress in operational transformation and growth strategy across its dental and medical segments, with a focus on building a leaner organization for sustained growth and improved profitability [1][2]. Financial Performance - For Q3 2025, revenues were approximately $2.4 million, a slight decrease from $2.5 million in Q3 2024, primarily due to lower domestic dental sales, partially offset by higher international dental sales and recurring medical revenue [3]. - Gross profit for Q3 2025 was approximately $1.6 million, or 70% of revenue, compared to $1.8 million, or 73% of revenue, in Q3 2024 [3]. - The operating loss for Q3 2025 was approximately $(1.1) million, an improvement of approximately $0.3 million, or 23%, from $(1.5) million in Q3 2024, attributed to lower selling, general, and administrative expenses [3]. - The net loss for Q3 2025 was approximately $(1.2) million, or $(0.01) per share, compared to a net loss of $(1.5) million, or $(0.02) per share, in Q3 2024 [3]. Year-to-Date Results - For the nine months ended September 30, 2025, revenues were approximately $6.9 million, an increase of approximately $0.3 million, or 5%, from $6.6 million in the same period of 2024, driven by growth in international dental sales and higher recurring revenue from the medical segment [4]. - Gross profit for the nine months ended September 30, 2025, was approximately $4.9 million, or 71% of revenue, consistent with the previous year [4]. - The operating loss for the nine months ended September 30, 2025, was approximately $(4.6) million, slightly improved from $(4.7) million in the same period of 2024 [4]. - The net loss for the nine months ended September 30, 2025, was approximately $(4.6) million, or $(0.06) per share, compared to a net loss of $(2.7) million, or $(0.03) per share, in the same period of 2024 [4]. Cash Position - As of September 30, 2025, the company reported cash and cash equivalents of approximately $1.3 million and working capital of approximately $3.1 million [5]. Strategic Initiatives - The company is expanding its direct sales programs in North America and securing new international registrations for its STA® Single Tooth Anesthesia System, while enhancing its omnichannel digital marketing strategy [2]. - There is growing utilization and recurring revenue from CompuFlo® disposables, with increasing interest from hospitals and international distributors [2]. - The company is advancing its reimbursement strategy for CompuFlo®, focusing on securing Medicare payment-rate assignments and expanding commercial coverage, which are seen as key enablers for broader adoption [2].